|
Celecoxib in Treating Patients With Bladder Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Celecoxib in Treating Patients With Bladder Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Celecoxib in Treating Patients With Bladder Cancer Clinical research trials and Celecoxib in Treating Patients With Bladder Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Celecoxib in Treating Patients With Bladder Cancer. Celecoxib in Treating Patients With Bladder Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Celecoxib in Treating Patients With Bladder Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Celecoxib in Treating Patients With Bladder Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Celecoxib in Treating Patients With Bladder Cancer  Celecoxib in Treating Patients With Bladder Cancer
Celecoxib in Treating Patients With Bladder Cancer
For Condition: recurrent bladder cancer
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of bladder cancer. PURPOSE: Randomizedphase IIb/III trial to study the effectiveness of celecoxib in preventing disease recurrence in patients who have bladder cancer.
Details: OBJECTIVES: - Compare the time to recurrence after treatment with celecoxib vs placebo in patients with superficial transitional cell carcinoma of the bladder at high risk for recurrence. - Correlate the modulation of one or more biomarkers with recurrence of bladder cancer and confirm the value of the marker(s) as a surrogate endpoint biomarker for bladder cancer and celecoxib. - Determine the toxicity of celecoxib in these patients. - Compare the quality of life of patients treated with these regimens. OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to center and presence of Tis disease (yes vs no). Patients are randomized to one of two arms. - Arm I: Patients receive oral celecoxib twice daily. - Arm II: Patients receive oral placebo twice daily. Treatment continues in both arms for 1-2 years in the absence of unacceptable toxicity, development of recurrent or invasive bladder carcinoma, or development of a second malignancy requiring radiotherapy or systemic therapy. Quality of life is assessed at baseline and at week 54. Patients are followed at 6 weeks and then every 12 weeks until the last randomized patient has been on the study for 1 year or until disease recurrence. PROJECTED ACCRUAL: A total of 152 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven superficial transitional cell carcinoma of the bladder at high risk for recurrence, meeting 1 of the following staging criteria: - Stage Ta (grade 3 OR multifocal OR at least 2 occurrences, including current tumor, within the past 12 months) - Stage T1 (any grade) - Stage Tis - Patients with Ta or T1 lesions must have undergone complete transurethral resection of bladder tumor within the past 9 months - No carcinoma involving the prostatic urethra or upper urinary tract - Must have received the following prior to randomization: - Induction course of BCG comprising 6 weekly intravesical doses (at least 4 doses if BCG intolerant) - Additional induction courses of BCG allowed - Maintenance course of BCG comprising 3 weekly doses (at least 1 dose if BCG intolerant) - No evidence of disease by cystoscopy (with or without biopsy) and bladder cytology prior to initiation of maintenance BCG - Concurrent interferon allowed PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Zubrod 0-2 OR - ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - WBC at least 3,000/mm^3 - Hemoglobin at least lower limit of normal - Platelet count at least 125,000/mm^3 - No significant bleeding disorder Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - SGOT and SGPT no greater than 1.5 times ULN - No chronic or acute hepatic disorder Renal: - Creatinine no greater than 1.5 times ULN - No chronic or acute renal disorder - Normal kidneys and ureters on imaging study within the past 9 months Gastrointestinal: - No active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) - No active pancreatitis - No esophageal, gastric, pyloric channel, or duodenal ulceration that was diagnosed or treated within the past 30 days Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No other medical or psychological condition that would preclude study participation - No hypersensitivity or adverse reactions to sulfonamides, cyclooxygenase (COX)-2 inhibitors, salicylates, or other NSAIDs - No other prior malignancy within the past 5 years except: - Nonmelanomatous skin cancer cured by excision - Carcinoma in situ of the cervix - Stage 0 chronic lymphocytic leukemia - Other malignancy for which patient has no current evidence of disease, has received no therapy within the past 6 months, has no concurrent or planned therapy, and has an expected disease-free survival of at least 5 years PRIOR CONCURRENT THERAPY: Biologic therapy: - See Disease Characteristics - No concurrent immunotherapy Chemotherapy: - No concurrent chemotherapy Endocrine therapy: - No concurrent oral or IV corticosteroids for more than 2 consecutive weeks or orally inhaled corticosteroids for more than 4 consecutive weeks during any 6 month period of the study - Chronic nasally inhaled steroids allowed provided patient agrees to use mometasone or, in countries where mometasone is not available, fluticasone - No other concurrent hormonal therapy except hormone replacement (i.e., estrogen or thyroid hormone replacement) Radiotherapy: - No prior pelvic radiotherapy - No concurrent radiotherapy Surgery: - See Disease Characteristics Other: - At least 30 days since prior investigational medication - At least 2 weeks since prior aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) except cardioprotective dose (no greater than 100 mg/day) of aspirin - No concurrent chronic NSAIDs except oral cardioprotective dose (no greater than 100 mg/day) of aspirin - Concurrent chronic use is defined as a frequency of at least 3 times per week for more than 2 consecutive weeks per year - No other concurrent investigational drug - No other concurrent systemic therapy - No concurrent lithium or fluconazole
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AnitaSabichi, Study Chair, M.D. Anderson Cancer Center
University of Texas Health Science Center at San Antonio *Recruiting*
San Antonio, Texas, 78229-3900
United States
Recruiting Joseph Basler 210-567-5643
University of Texas - MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030-4009
United States
Recruiting Anita Sabichi 713-745-4928
Baylor College of Medicine *Recruiting*
Houston, Texas, 77030
United States
Recruiting Seth Lerner 713-798-5906
Additional Information:
Study ID Numbers: CDR0000068139; NCI-P00-0165,MDA-ID-99368,SC-NQ4-99-02-006
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006124
Other Recurrent Bladder Cancer Studies:
1. Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer
2. BCG Plus Interferon alfa 2b in Treating Patients With Bladder Cancer
3. Suramin in Treating Patients With Recurrent Bladder Cancer
4. SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
5. Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
Related Studies:
Other recurrent bladder cancer Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Celecoxib in Treating Patients With Bladder Cancer
|
|
|
|
|
|
|
|
